Researchers Identify Active Fragment of Doping Agent TB-500, Develop Detection Method

The compound TB-500 has long been suspected as a performance-enhancing substance in sports, but its exact active components and reliable detection methods have been elusive. Thymosin beta 4 is a naturally occurring peptide involved in cell migration, wound healing, and angiogenesis (new blood vessel formation), and its synthetic derivatives like TB-500 are believed to offer similar regenerative benefits, making them attractive to athletes. This study addresses the crucial need to identify the specific active peptide fragment within TB-500 and develop robust analytical strategies for its detection in biological samples.

Using advanced analytical techniques, the study successfully identified a specific peptide fragment within the commercial TB-500 formulation. This fragment was confirmed to be Ac-LKKTETQ, the N-terminal acetylated 17-23 fragment of human thymosin beta 4. The identity of this detected fragment was rigorously confirmed by comparing its spectroscopic properties to a synthetically produced standard of Ac-LKKTETQ, ensuring 100% match in chemical structure. The research also outlined a practical analytical strategy, suggesting that HPLC/LRMS could be effectively used for detecting Ac-LKKTETQ in plasma and urine samples, offering a sensitive and specific method for anti-doping control. This provides a concrete target for future substance abuse detection efforts. The study definitively identified and characterized Ac-LKKTETQ as the active N-terminal acetylated 17-23 fragment of thymosin beta 4 present in TB-500, confirming its chemical structure and providing a reference standard.